Protein-Functionalized PLGA Nanoparticles of Lamotrigine for Neuropathic Pain Management

AAPS PharmSciTech

Volumn 16, Issue 2, 2015, Pages 413-427

  Lalani, Jigar ^a   Patil, Sushilkumar ^a   Kolate, Atul ^a   Lalani, Riddhi ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

brain targeting; factorial design; lactoferrin; lamotrigine; transferrin

Indexed keywords

ANTIBIOTIC AGENT; LACTOFERRIN; LAMOTRIGINE; NANOCARRIER; POLYGLACTIN; TRANSFERRIN; ANALGESIC AGENT; LACTIC ACID; LIGAND; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN; TRIAZINE DERIVATIVE;

ANALGESIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG STABILITY; ELIMINATION HALF-LIFE; FACTORIAL DESIGN; GAMMA SCINTIGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NEUROPATHIC PAIN; NONHUMAN; ORGAN DISTRIBUTION; PAIN THRESHOLD; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SCIATIC NERVE INJURY; SKIN SENSITIZATION; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION; TREATMENT RESPONSE; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; FEMALE; MALE; NEURALGIA; PARTICLE SIZE;

ANALGESICS; ANIMALS; BRAIN; FEMALE; LACTIC ACID; LACTOFERRIN; LIGANDS; MALE; MICE; NANOPARTICLES; NEURALGIA; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTEINS; TISSUE DISTRIBUTION; TRANSFERRIN; TRIAZINES;

EID: 84925794121     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0235-3     Document Type: Article

References (50)

1. Walid MS, Donahue SN, Darmohray DM, Hyer Jr LA, Robinson Jr JS. The fifth vital sign—what does it mean? Pain Pract Off J World Inst Pain. 2008;8(6):417–22.
2. Colombo B, Annovazzi PO, Comi G. Medications for neuropathic pain: current trends. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2006;27 Suppl 2:S183–9.
3. Nitu AN, Wallihan R, Skljarevski V, Ramadan NM. Emerging trends in the pharmacotherapy of chronic pain. Expert Opin Investig Drugs. 2003;12(4):545–59.
4. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Phys. 2008;11(2 Suppl):S105–20.
5. Eisenberg E, Shifrin A, Krivoy N. Lamotrigine for neuropathic pain. Expert Rev Neurother. 2005;5(6):729–35.
6. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe H-C. Lamotrigine and toxic epidermal necrolysis. Lancet. 1996;348(9041):1597.
7. Castel-Branco M, Lebre V, Falcao A, Figueiredo I, Caramona M. Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. Eur J Pharmacol. 2003;482(1–3):163–8.
8. Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol. 2000;130(2):242–8.
9. Loscher W, Ganter M, Fassbender CP. Correlation between drug and metabolite concentrations in plasma and anesthetic action of ketamine in swine. Am J Vet Res. 1990;51(3):391–8.
10. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991;35(6):1208–13.
11. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–49.
12. Xie Y, Bagby TR, Cohen MS, Forrest ML. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv. 2009;6(8):785–92.
13. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387–422.
14. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65–81.
15. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm. 2003;6(2):252–73.
16. Begley DJ. The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol. 1996;48(2):136–46.
17. Su Y, Sinko PJ. Drug delivery across the blood–brain barrier: why is it difficult? How to measure and improve it? Expert Opin Drug Deliv. 2006;3(3):419–35.
18. Smith MW, Gumbleton M. Endocytosis at the blood–brain barrier: from basic understanding to drug delivery strategies. J Drug Target. 2006;14(4):191–214.
19. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162–3.
20. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaissa M, Spik G, et al. Receptor-mediated transcytosis of lactoferrin through the blood–brain barrier. J Biol Chem. 1999;274(11):7011–7.
21. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release Off J Control Release Soc. 2009;134(1):55–61.
22. Huang R, Ke W, Han L, Liu Y, Shao K, Jiang C, et al. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull. 2010;81(6):600–4.
23. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1–4.
24. Lalani J, Raichandani Y, Mathur R, Lalan M, Chutani K, Mishra AK, et al. Comparative receptor based brain delivery of tramadol-loaded poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol. 2012;8(6):918–27.
25. Huang YB, Tsai YH, Lee SH, Chang JS, Wu PC. Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. Int J Pharm. 2005;289(1–2):87–95.
26. Akhnazarova S, Kafarov V. Experiment optimization in chemistry and chemical engineering. 1982.
27. Derringer G, Suich R. Simultaneous-optimization of several response variables. J Qual Technol. 1980;12(4):214–9.
28. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2(5):373–83.
29. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002;19(8):1137–43.
30. Joshi DP, Lan-Chun-Fung YL, Pritchard JG. Determination of poly(vinyl alcohol) via its complex with boric acid and iodine. Anal Chim Acta. 1979;104(1):153–60.
31. Babbar A, Kashyap R, Chauhan UP. A convenient method for the preparation of 99mTc-labelled pentavalent DMSA and its evaluation as a tumour imaging agent. J Nucl Biol Med (Turin, Italy: 1991). 1991;35(2):100–4.
32. Theobald AE. Textbook of radiopharmacy: theory and practice. Gordon and Breach Science Publishers; 1994.
33. Saha GB, Go RT, MacIntyre WJ. Radiopharmaceuticals for cardiovascular imaging. Int J Radiat Appl Instrum B Nucl Med Biol. 1992;19(1):1–20.
34. Saha GB, MacIntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. Semin Nucl Med. 1994;24(4):324–49.
35. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm. 2004;281(1–2):25–33.
36. ISO 10993-10:2010 Biological evaluation of medical devices—part 10: tests for irritation and skin sensitization ISO. 2010.
37. Proust B, Astier C, Renaudin JM, Magueur E, Maurice D, Belcourt C, et al. A murine model of cow’s milk protein-induced allergic reaction: use for safety assessment of hidden milk allergens. Eur Ann Allergy Clin Immunol. 2009;41(3):85–94.
38. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43(2):205–18.
39. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88.
40. Manoocheheri S, Darvishi B, Kamalinia G, Amini M, Fallah M, Ostad SN, et al. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru J Fac Pharm Tehran Univ Med Sci. 2013;21(1):58.
41. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release Off J Control Release Soc. 2002;82(1):105–14.
42. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282–95.
43. Feng SS. Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev Med Devices. 2004;1(1):115–25.
44. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. CRC Press; 2001.
45. Talukder MJ, Takeuchi T, Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci Jpn Soc Vet Sci. 2003;65(9):957–64.
46. Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. Int J Pharm. 2009;379(2):285–92.
47. Broadwell RD, Baker-Cairns BJ, Friden PM, Oliver C, Villegas JC. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood–brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp Neurol. 1996;142(1):47–65.
48. Suzuki YA, Lonnerdal B. Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol Biochim Biol Cell. 2002;80(1):75–80.
49. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, et al. Regulation of expression of murine transferrin receptor 2. Blood. 2001;98(6):1949–54.
50. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, et al. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci U S A. 2000;97(5):2214–9.